152 related articles for article (PubMed ID: 11935377)
21. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Ganea D; Delgado M
Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
[TBL] [Abstract][Full Text] [Related]
22. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
Sun W; Tadmori I; Yang L; Delgado M; Ganea D
J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.
Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP
J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753
[TBL] [Abstract][Full Text] [Related]
24. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Ganea D; Rodriguez R; Delgado M
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
[TBL] [Abstract][Full Text] [Related]
26. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
27. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
28. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity.
Brenneman DE; Hauser JM; Spong C; Phillips TM
Neuropeptides; 2002 Aug; 36(4):271-80. PubMed ID: 12372701
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
Delgado M; Leceta J; Gomariz RP; Ganea D
J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.
Dejda A; Sokołowska P; Nowak JZ
Pharmacol Rep; 2005; 57(3):307-20. PubMed ID: 15985713
[TBL] [Abstract][Full Text] [Related]
31. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 Oct; 297(5):1181-5. PubMed ID: 12372411
[TBL] [Abstract][Full Text] [Related]
33. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies.
Martinez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Neuroimmunol; 1998 May; 85(2):155-67. PubMed ID: 9630164
[TBL] [Abstract][Full Text] [Related]
34. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
35. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
37. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
Ganea D; Delgado M
Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.
Hedlund P; Alm P; Ekström P; Fahrenkrug J; Hannibal J; Hedlund H; Larsson B; Andersson KE
Br J Pharmacol; 1995 Oct; 116(4):2258-66. PubMed ID: 8564257
[TBL] [Abstract][Full Text] [Related]
39. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
40. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
